vs

Side-by-side financial comparison of PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) and Tempus AI, Inc. (TEM). Click either name above to swap in a different company.

Tempus AI, Inc. is the larger business by last-quarter revenue ($367.2M vs $44.6M, roughly 8.2× PACIFIC BIOSCIENCES OF CALIFORNIA, INC.). Tempus AI, Inc. runs the higher net margin — -14.8% vs -90.4%, a 75.7% gap on every dollar of revenue. On growth, Tempus AI, Inc. posted the faster year-over-year revenue change (83.0% vs 13.8%). PACIFIC BIOSCIENCES OF CALIFORNIA, INC. produced more free cash flow last quarter ($-19.9M vs $-41.5M). Over the past eight quarters, Tempus AI, Inc.'s revenue compounded faster (58.7% CAGR vs 7.3%).

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

Tempus AI, Inc. is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM."

PACB vs TEM — Head-to-Head

Bigger by revenue
TEM
TEM
8.2× larger
TEM
$367.2M
$44.6M
PACB
Growing faster (revenue YoY)
TEM
TEM
+69.2% gap
TEM
83.0%
13.8%
PACB
Higher net margin
TEM
TEM
75.7% more per $
TEM
-14.8%
-90.4%
PACB
More free cash flow
PACB
PACB
$21.6M more FCF
PACB
$-19.9M
$-41.5M
TEM
Faster 2-yr revenue CAGR
TEM
TEM
Annualised
TEM
58.7%
7.3%
PACB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PACB
PACB
TEM
TEM
Revenue
$44.6M
$367.2M
Net Profit
$-40.4M
$-54.2M
Gross Margin
37.1%
Operating Margin
-92.3%
-16.7%
Net Margin
-90.4%
-14.8%
Revenue YoY
13.8%
83.0%
Net Profit YoY
-1802.7%
-316.2%
EPS (diluted)
$-0.11
$-0.30

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PACB
PACB
TEM
TEM
Q4 25
$44.6M
$367.2M
Q3 25
$38.4M
$334.2M
Q2 25
$39.8M
$314.6M
Q1 25
$37.2M
$255.7M
Q4 24
$39.2M
$200.7M
Q3 24
$40.0M
$180.9M
Q2 24
$36.0M
$166.0M
Q1 24
$38.8M
$145.8M
Net Profit
PACB
PACB
TEM
TEM
Q4 25
$-40.4M
$-54.2M
Q3 25
$-38.0M
$-80.0M
Q2 25
$-41.9M
$-42.8M
Q1 25
$-426.1M
$-68.0M
Q4 24
$2.4M
$-13.0M
Q3 24
$-60.7M
$-75.8M
Q2 24
$-173.3M
$-552.2M
Q1 24
$-78.2M
$-64.7M
Gross Margin
PACB
PACB
TEM
TEM
Q4 25
37.1%
Q3 25
41.4%
Q2 25
36.9%
Q1 25
-3.7%
Q4 24
25.6%
Q3 24
25.0%
Q2 24
16.5%
Q1 24
29.1%
Operating Margin
PACB
PACB
TEM
TEM
Q4 25
-92.3%
-16.7%
Q3 25
-101.1%
-18.3%
Q2 25
-112.8%
-19.6%
Q1 25
-1154.5%
-26.9%
Q4 24
-390.1%
-25.3%
Q3 24
-160.3%
-29.6%
Q2 24
-488.3%
-321.4%
Q1 24
-209.6%
-36.5%
Net Margin
PACB
PACB
TEM
TEM
Q4 25
-90.4%
-14.8%
Q3 25
-98.9%
-23.9%
Q2 25
-105.4%
-13.6%
Q1 25
-1146.8%
-26.6%
Q4 24
6.0%
-6.5%
Q3 24
-151.9%
-41.9%
Q2 24
-481.3%
-332.7%
Q1 24
-201.4%
-44.4%
EPS (diluted)
PACB
PACB
TEM
TEM
Q4 25
$-0.11
$-0.30
Q3 25
$-0.13
$-0.46
Q2 25
$-0.14
$-0.25
Q1 25
$-1.44
$-0.40
Q4 24
$-0.44
$2.56
Q3 24
$-0.22
$-0.46
Q2 24
$-0.64
$-6.86
Q1 24
$-0.29
$-1.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PACB
PACB
TEM
TEM
Cash + ST InvestmentsLiquidity on hand
$279.5M
$604.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$5.3M
$491.3M
Total Assets
$784.1M
$2.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PACB
PACB
TEM
TEM
Q4 25
$279.5M
$604.8M
Q3 25
$298.7M
$655.9M
Q2 25
$314.7M
$186.3M
Q1 25
$343.1M
$151.6M
Q4 24
$389.9M
$341.0M
Q3 24
$471.1M
$388.0M
Q2 24
$509.8M
$478.8M
Q1 24
$561.9M
$79.9M
Stockholders' Equity
PACB
PACB
TEM
TEM
Q4 25
$5.3M
$491.3M
Q3 25
$36.1M
$507.8M
Q2 25
$61.5M
$309.6M
Q1 25
$91.6M
$326.2M
Q4 24
$506.6M
$56.3M
Q3 24
$453.1M
$53.7M
Q2 24
$492.7M
$98.3M
Q1 24
$649.0M
$-1.5B
Total Assets
PACB
PACB
TEM
TEM
Q4 25
$784.1M
$2.3B
Q3 25
$803.2M
$2.3B
Q2 25
$825.5M
$1.6B
Q1 25
$860.8M
$1.5B
Q4 24
$1.3B
$926.1M
Q3 24
$1.5B
$971.7M
Q2 24
$1.5B
$864.6M
Q1 24
$1.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PACB
PACB
TEM
TEM
Operating Cash FlowLast quarter
$-19.1M
$-36.8M
Free Cash FlowOCF − Capex
$-19.9M
$-41.5M
FCF MarginFCF / Revenue
-44.6%
-11.3%
Capex IntensityCapex / Revenue
1.9%
1.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-114.1M
$-239.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PACB
PACB
TEM
TEM
Q4 25
$-19.1M
$-36.8M
Q3 25
$-18.7M
$-119.8M
Q2 25
$-29.4M
$44.2M
Q1 25
$-44.1M
$-105.6M
Q4 24
$-30.6M
Q3 24
$-45.5M
$48.7M
Q2 24
$-54.3M
$-97.1M
Q1 24
$-75.7M
$-101.4M
Free Cash Flow
PACB
PACB
TEM
TEM
Q4 25
$-19.9M
$-41.5M
Q3 25
$-18.8M
$-126.5M
Q2 25
$-29.9M
$36.6M
Q1 25
$-45.4M
$-107.7M
Q4 24
$-32.3M
Q3 24
$-46.3M
$48.6M
Q2 24
$-55.7M
$-105.1M
Q1 24
$-79.6M
$-107.5M
FCF Margin
PACB
PACB
TEM
TEM
Q4 25
-44.6%
-11.3%
Q3 25
-48.9%
-37.9%
Q2 25
-75.3%
11.6%
Q1 25
-122.3%
-42.1%
Q4 24
-82.3%
Q3 24
-115.7%
26.9%
Q2 24
-154.8%
-63.3%
Q1 24
-205.0%
-73.7%
Capex Intensity
PACB
PACB
TEM
TEM
Q4 25
1.9%
1.3%
Q3 25
0.2%
2.0%
Q2 25
1.4%
2.4%
Q1 25
3.7%
0.8%
Q4 24
4.1%
Q3 24
2.0%
0.0%
Q2 24
4.1%
4.8%
Q1 24
10.0%
4.2%
Cash Conversion
PACB
PACB
TEM
TEM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-12.93×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PACB
PACB

Products$39.0M87%
Service And Other$5.7M13%

TEM
TEM

Segment breakdown not available.

Related Comparisons